<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Radiotherapy and Imaging</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DB09A3ED-2068-4491-8C53-6830B2CDF9C1"><gtr:id>DB09A3ED-2068-4491-8C53-6830B2CDF9C1</gtr:id><gtr:firstName>Penelope</gtr:firstName><gtr:surname>Hopwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/303A1CBE-C778-4A59-B054-0BB30FE04502"><gtr:id>303A1CBE-C778-4A59-B054-0BB30FE04502</gtr:id><gtr:firstName>Judith</gtr:firstName><gtr:surname>Bliss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2A940A47-40A7-4C63-AE8E-7EFD3D48728E"><gtr:id>2A940A47-40A7-4C63-AE8E-7EFD3D48728E</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Yarnold</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9600656"><gtr:id>69D5C7AB-944F-4B88-AD2F-5FB3C6905857</gtr:id><gtr:title>Standardisation of Radiotherapy (START) Trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9600656</gtr:grantReference><gtr:abstractText>The patient advocate group Radiotherapy Action Group Exposure (R.A.G.E.) has become a strong supporter of the START initiative over the years, with 2 members represented on the Trial Management Group. Issues relating to radiotherapy fractionation have emerged repeatedly in the media over the last 20 years. The understanding of scientific issues by the majority of lay people and a minority of professionals has been poor. The trial has achieved a high public profile across the UK including a discussion on Panorama. A highly productive debate has changed the climate, with the importance of evidence based medicine acknowledged by all parties.</gtr:abstractText><gtr:technicalSummary>Breast radiotherapy is delivered as a series of small 
doses (fractions). The international standard delivers
25 fractions of 2.0 Gy over 5 weeks (Gy = unit of 
radiation dose). Alternative UK schedules give a 
smaller number of slightly larger fractions e.g. 
15 fractions of 2.67 Gy over 3 weeks. 
If simpler schedules prove to be at least as safe 
and effective as the international standard, their 
adoption will benefit patients and health services. 
The START trial tests the hypothesis that schedules 
using fractions slightly larger than 2.0 Gy are safe 
and effective alternatives to the international 
standard.</gtr:technicalSummary><gtr:fund><gtr:end>2009-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2079377</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (USA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIH 01: A genome wide association study for the identification of radiation-induced normal tissue toxicity in breast cancer patients treated with radiotherapy</gtr:description><gtr:id>651E7F62-7E6D-4857-A239-A120364E5E77</gtr:id><gtr:impact>This grant application was rejected but we are intending reapplying in 2011.</gtr:impact><gtr:partnerContribution>Co-applicant on an NIH grant application.Co-applicant on an NIH grant application.</gtr:partnerContribution><gtr:piContribution>We have jointly submitted this grant application to the NIH in America.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>New York University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine NYU</gtr:department><gtr:description>NIH 01: A genome wide association study for the identification of radiation-induced normal tissue toxicity in breast cancer patients treated with radiotherapy</gtr:description><gtr:id>2550C0C2-D2CD-499E-BB64-5D4A2C68BE3C</gtr:id><gtr:impact>This grant application was rejected but we are intending reapplying in 2011.</gtr:impact><gtr:partnerContribution>Co-applicant on an NIH grant application.Co-applicant on an NIH grant application.</gtr:partnerContribution><gtr:piContribution>We have jointly submitted this grant application to the NIH in America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lay Summary for patients</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DA56430C-5717-46E2-8EC1-B827FBF813F0</gtr:id><gtr:impact>We wrote a lay summary of the published trial results for the participants in the trial. This was then circulated to the recruiting centres to send or give out to the patients.

We are not aware of any impact of this policy.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancet Oncology press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4CEEE69-C9C8-4879-A98B-0C9203735820</gtr:id><gtr:impact>This was the press release for the 10 year results of the START trial which was written by Lancet Oncology.

There were a lot of articles in national press.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECC 2013 press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EFF76A75-6CA6-444E-8C88-386C66E90B08</gtr:id><gtr:impact>The organisers of the conference ECC2013 decided to release a press statement for the poster presentation as the results were thought to be highly significant for the radotherapy community.

There was a lot of press coverage for the results of this poster.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentation at European Cancer Congress 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F0E8A2D2-3B42-4F69-8159-B7D32A3E9919</gtr:id><gtr:impact>The poster was selected for a poster presentation at ECC 2013 and presented important results about wasted radiotherapy dose during treatment for breast cancer. The title and authors of the poster were: Estimation of an overall treatment time factor for local relapse after adjuvant radiotherapy for early breast cancer in the START hypofractionation trials (CRUK/96/001); JS Haviland, SM Bentzen, M Sydenham, JR Owen, JM Bliss, JR Yarnold on behalf of the START Trialists' Group.

There was a lot of press coverage of these results.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release to accompany ASCO presentation</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BC82D0C4-5F99-471E-88B3-0B853EB2608E</gtr:id><gtr:impact>The START trial presentation was selected for ASCO press coverage, which comprised a press conference and a press release. This is only for those presentations considered &amp;quot;Best at ASCO&amp;quot;.

We were approached by Lancet to pubish the results in their journal.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release San Antonio Dec 2012</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF5132F0-1990-4FE0-9D75-F285544EF476</gtr:id><gtr:impact>The START trial 10 year results were chosen by the San Antonio Conference for their press conference.

The press conference was attended by press from North America and Europe</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>San Antonio Breast Cancer Conference 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>25A7A9FB-7099-4F52-82F2-95ABA2DB74E5</gtr:id><gtr:impact>The conference attracts nearly 10000 participants from 100 countries, all breast cancer specialists. The abtract title and authors are:
The UK START (Standardisation of Breast Radiotherapy) Trials; 10-year follow-up results. Joanne S Haviland, Rajiv Agrawal, Edwin Aird, Jane Barrett, Peter Barrett-Lee, Jackie Brown, John Dewar, Jane Dobbs, Penelope Hopwood, Peter Hoskin, Pat Lawton, Brian Magee, Judith Mills, David Morgan, Roger Owen, Joyce Pritchard, Sandra Simmons, Mark Sydenham, Karen Venables, Judith M Bliss, John R Yarnold.

The results of the START trial will be used in a meta analysis with other hypofractionation trials.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release from CRUK</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9AEAC5FE-9AC9-4652-ADDA-224E000EF379</gtr:id><gtr:impact>This was a press release from the funders to accompany the 10 year results of the START trial when published in Lancet Oncology

Lots of coverage of the trial results in the national press.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>182524</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Protection Agency</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Public Health England (formerly: Health Protection Agency)</gtr:fundingOrg><gtr:id>3953403E-F61F-4031-BBBE-9C7C27EB6CEA</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>CTAAC Clinical Trials Advisory &amp; Awards</gtr:department><gtr:description>Clinical Trials Awards &amp;amp; Advisory Committee - Late Phase Study</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:fundingRef>C1491/A16831</gtr:fundingRef><gtr:id>A157B512-56EA-4BEF-A7E9-BEF2D27FF941</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Clinical Trials Award - HOT II/Cancer Research UK (CRUK) and Department of Health</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:fundingRef>C181/A9694</gtr:fundingRef><gtr:id>BA7F1E17-D5D6-4273-AB11-65851A605311</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>234385</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Award - HOT II/Cancer Research UK (CRUK) and Department of Health</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:fundingRef>C181/A9694</gtr:fundingRef><gtr:id>8FD1B4B3-C9C5-46C8-9FBD-CB3B028B5213</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160257</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:fundingRef>PR11</gtr:fundingRef><gtr:id>97C499B8-67F4-413F-B3A6-0CCC1AB1B1E7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC FP6 (EURATOM)</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>FI6R-036452</gtr:fundingRef><gtr:id>258F55C0-29F0-4790-86DB-6F46032AFCAB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>126783</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Grant - RACE(S)</gtr:description><gtr:end>2008-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:fundingRef>C181/A6976</gtr:fundingRef><gtr:id>B9C8DEE2-B101-42DF-9DB8-85F33FC2E27C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27179</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR Research Capability Funding</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>D1790EBD-DDAD-491B-9994-D1A9FD5E8256</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3639054</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR Health Technology Assessment programme FAST-Forward</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:fundingRef>09/01/47</gtr:fundingRef><gtr:id>0CCC9E3B-F9DD-4E8C-94CB-E86A6193AFA6</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>70272D6F-C48A-4857-9B3A-CF3566881130</gtr:id><gtr:impact>The new radiotherapy regimen delivers a curative post-surgical treatment for localised breast cancer that is gentler on the healthy tissues and non-inferior in terms of cancer cure.
A shorter treatment regimen has allowed more patients to be treated at radiotherapy centres. 
It has also saved the NHS money as many fewer treatment sessions have been needed.</gtr:impact><gtr:type>Citation in systematic reviews</gtr:type><gtr:url>http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003860.pub4/abstract</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a clinical trial testing hypofractionated radiotherapy for the treatment of early breast cancer.</gtr:description><gtr:id>2606CF83-580F-4023-A844-3F805F2977D7</gtr:id><gtr:impact>The reduced fractionation in the START trials is now UK standard of care.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>START clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:ukcrnIsctnId>ISRCTN59368779</gtr:ukcrnIsctnId></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC161EA1-FC08-4E36-9A67-97CF1ED8E805"><gtr:id>BC161EA1-FC08-4E36-9A67-97CF1ED8E805</gtr:id><gtr:title>OC-0392: Tumour characteristics associated with local relapse after hypofractionated radiotherapy in early breast cancer</gtr:title><gtr:parentPublicationTitle>Radiotherapy and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2148CD4-DE9C-4B0B-9DD3-9854430B4952"><gtr:id>B2148CD4-DE9C-4B0B-9DD3-9854430B4952</gtr:id><gtr:title>What is the optimum breast plan: a study based on the START trial plans.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f9d854988cf3675d94896a0e22fdfe4"><gtr:id>8f9d854988cf3675d94896a0e22fdfe4</gtr:id><gtr:otherNames>Venables K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB2E3992-4C6D-41B0-8725-EC5F120F7DAF"><gtr:id>CB2E3992-4C6D-41B0-8725-EC5F120F7DAF</gtr:id><gtr:title>XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71b750891f077fec864d26bebbcfb7bf"><gtr:id>71b750891f077fec864d26bebbcfb7bf</gtr:id><gtr:otherNames>Seibold P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46A2A7DC-9BA0-482C-BB8C-E7AF15FD20A2"><gtr:id>46A2A7DC-9BA0-482C-BB8C-E7AF15FD20A2</gtr:id><gtr:title>The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24A252A8-9817-46DA-ADE3-B91EA727C190"><gtr:id>24A252A8-9817-46DA-ADE3-B91EA727C190</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7e46bc9eb30d08d17dc3b248661226e6"><gtr:id>7e46bc9eb30d08d17dc3b248661226e6</gtr:id><gtr:otherNames>START Trialists' Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FE2323E-F111-40DD-8BAD-44854C8ED367"><gtr:id>5FE2323E-F111-40DD-8BAD-44854C8ED367</gtr:id><gtr:title>Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/842478FA-9438-4A56-8DDE-04AA25805052"><gtr:id>842478FA-9438-4A56-8DDE-04AA25805052</gtr:id><gtr:title>Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b9a41bdc7e102320c48c4c3c51c8189"><gtr:id>6b9a41bdc7e102320c48c4c3c51c8189</gtr:id><gtr:otherNames>Miles EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C881DF2-8EEC-4A5C-A044-3C9BC2DD4F85"><gtr:id>9C881DF2-8EEC-4A5C-A044-3C9BC2DD4F85</gtr:id><gtr:title>Does participation in clinical trials influence the implementation of new techniques? A look at changing techniques in breast radiotherapy in the UK.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f9d854988cf3675d94896a0e22fdfe4"><gtr:id>8f9d854988cf3675d94896a0e22fdfe4</gtr:id><gtr:otherNames>Venables K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACB34BC7-3701-4DA7-8F27-CA1AFD3AC4A6"><gtr:id>ACB34BC7-3701-4DA7-8F27-CA1AFD3AC4A6</gtr:id><gtr:title>The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START).</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E0C3DC6-F52C-4D27-9830-A363C6049DFD"><gtr:id>3E0C3DC6-F52C-4D27-9830-A363C6049DFD</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7e46bc9eb30d08d17dc3b248661226e6"><gtr:id>7e46bc9eb30d08d17dc3b248661226e6</gtr:id><gtr:otherNames>START Trialists' Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B214B89C-07A4-4F31-AE63-EEC4B56DF9CC"><gtr:id>B214B89C-07A4-4F31-AE63-EEC4B56DF9CC</gtr:id><gtr:title>Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49934792-A504-4809-A014-A6D1FB02B0C8"><gtr:id>49934792-A504-4809-A014-A6D1FB02B0C8</gtr:id><gtr:title>Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66AAA940-6D61-43B9-8BDF-4B70D15E41F0"><gtr:id>66AAA940-6D61-43B9-8BDF-4B70D15E41F0</gtr:id><gtr:title>Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf7159f832955f48b7a64134732f6f2e"><gtr:id>cf7159f832955f48b7a64134732f6f2e</gtr:id><gtr:otherNames>Hopwood P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/117145A7-CC8A-4F98-ABA6-210EB4A3F429"><gtr:id>117145A7-CC8A-4F98-ABA6-210EB4A3F429</gtr:id><gtr:title>Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/067DB994-BA88-4F8B-BFAF-BFB59491BD2A"><gtr:id>067DB994-BA88-4F8B-BFAF-BFB59491BD2A</gtr:id><gtr:title>Patient reported outcomes following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Presented on behalf of the START Trial Management Group</gtr:title><gtr:parentPublicationTitle>European Journal of Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d2a785ff36a73dbabb9a12771c5e73e"><gtr:id>9d2a785ff36a73dbabb9a12771c5e73e</gtr:id><gtr:otherNames>Griffin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F24635B-0139-4405-8AE0-57F6FB79A49C"><gtr:id>9F24635B-0139-4405-8AE0-57F6FB79A49C</gtr:id><gtr:title>Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0e489750c6d225b340afa2b876064f7"><gtr:id>b0e489750c6d225b340afa2b876064f7</gtr:id><gtr:otherNames>Somaiah N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB04FE12-2446-4BD8-AAC5-21824BEDFD65"><gtr:id>AB04FE12-2446-4BD8-AAC5-21824BEDFD65</gtr:id><gtr:title>The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86024c1d9431f553e3e1d02c4cc95031"><gtr:id>86024c1d9431f553e3e1d02c4cc95031</gtr:id><gtr:otherNames>Haviland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9600656</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>